8-K current report · filed Oct 27, 2026

Aclaris Therapeutics, Inc. (ACRS) 8-K Current Report: October 27, 2026

Item 2.02Item 7.01Item 8.01Item EX-99.1Item EX-99.2ACRS overview

Short answer

Aclaris Therapeutics, Inc. (ACRS) filed an 8-K current report with the SEC on October 27, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Item 2.02 points investors to Item 8.01 for Aclaris’ cash, cash equivalents and marketable securities as of September 30, 2026.

Aclaris Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Item 2.02 points investors to Item 8.01 for Aclaris’ cash, cash equivalents and marketable securities as of September 30, 2026
  • Liquidity disclosure is the filing’s only financial update, relevant to funding capacity and near-term operations

Item 7.01 · Regulation FD Disclosure

  • ATI-052 Phase 1b proof-of-concept primary analysis results announced in atopic dermatitis and asthma
  • Anti-TSLP/IL-4Rα bispecific antibody data marks an early clinical validation milestone for Aclaris’ pipeline
  • Webcast and conference call with slides planned to present the Results

Item 8.01 · Other Events

  • Preliminary cash, equivalents and marketable securities of $204.6M at September 30, 2026, supporting continued development but subject to material adjustment
  • ATI-052 showed 45% placebo-adjusted EASI improvement at day 57 in 14-patient atopic dermatitis trial
  • Asthma trial showed 59% FeNO reduction and 200 mL placebo-adjusted FEV1 improvement at day 15
  • Favorable early safety profile: no Grade 3 or 4 adverse events, discontinuations, or conjunctivitis
  • Company prioritizing ATI-052 in EoE, with Phase 2b initiation targeted for early 2027

Item EX-99.1 · Exhibit EX-99.1

  • Phase 1b proof-of-concept success for ATI-052 in AD and asthma, materially validating dual TSLP/IL-4Rα targeting
  • AD trial: 14 patients, 45% placebo-adjusted EASI improvement and 43% placebo-adjusted itch improvement at day 57
  • Asthma trial: 16 patients, single 480 mg dose produced 200 ml placebo-adjusted FEV1 improvement and 59% FeNO reduction at day 15
  • Favorable safety profile: no Grade 3 or 4 events, discontinuations, or conjunctivitis
  • EoE prioritized for Phase 2b early next year, concentrating capital and execution on the lead development opportunity

Item EX-99.2 · Exhibit EX-99.2

  • Phase 1b proof-of-concept achieved in atopic dermatitis and asthma, supporting ATI-052 advancement to Phase 2
  • Atopic dermatitis: 58% EASI reduction and 78% EASI-50 response versus 13% and 0% placebo at Day 57
  • Asthma: 59% FeNO reduction and 200 mL placebo-adjusted FEV1 improvement after one 480 mg dose
  • Favorable early safety: no serious or Grade 3/4 adverse events, discontinuations, or conjunctivitis observed
  • Key risk: small, uncontrolled Phase 1b datasets, with cross-trial comparisons explicitly not valid

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other Aclaris Therapeutics, Inc. 8-K filings

Get the next ACRS 8-K as it lands

Follow ACRS for push alerts, or ask the research agent what this filing means.